Innovent presents updated IBI363 data in colorectal cancer at ASCO 2025
June 02, 2025 | 16:26
New phase 1 findings highlight promise of first-in-class bispecific antibody fusion for advanced colorectal cancer.
Innovent Publishes 2024 ESG Report, Reaffirms Sustainability Pledge
May 19, 2025 | 14:46
With a clear roadmap for green innovation, Innovent doubles down on global responsibility and transparent impact.
Innovent Showcases Breakthrough Preclinical Data on Novel Antibodies at AACR 2025
April 28, 2025 | 08:00
Cutting-edge bispecific and tri-specific antibody therapies headline Innovent’s research portfolio.
Innovent to Showcase Breakthrough Clinical Data at ASCO 2025
April 24, 2025 | 14:20
Seven oral presentations will unveil novel immunotherapy insights, including IBI363, at one of oncology’s biggest global stages.
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 as Monotherapy for Advanced Pancreatic Cancer
January 16, 2025 | 07:03
Innovent Biologics, Inc., announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI343.
Innovent Announces Second New Drug Application of DOVBLERON was Approved by China's National Medical Products Administration
January 03, 2025 | 07:00
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases.
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
January 02, 2025 | 06:30
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases.
Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024
November 25, 2024 | 07:30
Innovent Biologics, Inc.,announces that nearly 10 accepted clinical data of its novel oncology molecules
Mobile Version